Authors

Avisi Technologies releases positive 12-month data from VITA Trial

The VITA Trial is a prospective pilot study on the VisiPlate Aqueous Shunt in patients with with open-angle glaucoma.

Demodex Blepharitis in a Contact Lens Wearer: Treatment Plan and Outcomes

A panelist discusses how treating demodex blepharitis with Lotilaner not only eliminates the anterior blepharitis symptoms but also improves meibomian gland function, with low recurrence rates after treatment and significant benefits for patient comfort and quality of life.

Ravi Patel, MD, shares ASCRS 2025 insights on enVista ASPIRE IOL user experience

Discover how real-world evidence shapes cataract surgery practices, highlighting user satisfaction with enhanced monofocal IOLs at the 2025 ASCRS Annual Meeting.

SAHARA trial demonstrates sustained TearCare benefits for evaporative DED

New findings confirm TearCare's long-term effectiveness for dry eye disease, showing significant patient improvements with minimal treatments over 2 years.

AAO 2025: Clinical outcomes of early vs delayed pegcetacoplan treatment in GA

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

Robert T. Chang, MD, from Stanford University discusses how large language models are transforming ophthalmology by enhancing patient communication, documentation, and education, while also addressing ethical considerations and potential future applications in glaucoma care.

Envision Summit 2025: Eradicating TRD

At the Envision Summit 2025 in San Juan, Puerto Rico, Kristen Nwanyanwu, MD, MBA, MHS, joined by her children, discussed her talk on eradicating TRD and the family-friendly environment of the conference.

Q&A: James Chelnis discusses AAO 2025 presentation on aesthetic facial surgery

Dr. James Chelnis explores innovative energy-based technologies in aesthetic facial surgery, emphasizing safety, personalized treatments, and future advancements in patient care.

Regeneron receives another CRL for its Eylea 8 mg

Regeneron faces another FDA setback for Eylea HD due to manufacturing issues, but plans for new facilities signal future production improvements.

EnVision Summit 2025: Complications in glaucoma surgery

At the EnVision Summit 2025 in San Juan, Puerto Rico, Tania Tai, Lucy Shen, and Shivani Kamat all gave insight into complications they have seen while performing glaucoma surgery.